Substantial revenue increase in Q4 2010

- Sales grew by +66.7% in the 4th quarter of 2010 vs. the 3rd quarter of 2010

STENTYS (FR0010949404 – STNT), a medical technology company that markets a new generation of innovative stents to treat acute myocardial infarction, today reports its 2010 annual revenues for the period ending on December 31 2010.

- Revenues in FY 2010*

<table>
<thead>
<tr>
<th>€ thousands*</th>
<th>H1 2010</th>
<th>H2 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>72.2</td>
<td>87.5</td>
</tr>
<tr>
<td></td>
<td>145.9</td>
<td>305.6</td>
</tr>
</tbody>
</table>

* The company began to sell its products during 2010. Therefore, no revenues were recognized in 2009.

Revenues in the 4th quarter of 2010 amounted to €145,900, compared to €87,500 in the 3rd quarter of 2010, an increase of +66.7%. Between the first and second semesters of 2010, activity increased by +223.3%, totalling €233,400 for the last 6 months of 2010. On December 31 2010, annual revenues added up to €305,600, in line with Company’s and market’s expectations.

- Cash position

On December 31 2010, STENTYS had a cash position of €22 million, in line again with Company’s anticipation and reflects the solidity of the Company’s balance sheet structure.

- Key 2010 events

Presentation of the Apposition II clinical trial results

On September 22, STENTYS announced the results of the Apposition II international clinical trial that enrolled 80 patients in six countries. The study indisputably demonstrated that the STENTYS stent eliminates malapposition compared with conventional stent. Malapposition exposes patients to serious risk of recurrence of the heart attack. The study confirmed the value of STENTYS breakthrough technology.

Launch of the Apposition III clinical trial

In December 2010, STENTYS announced the launch of the Apposition III international clinical trial of its self-apposing stent. The results of this trial, which will enrol 500 patients, will confirm the medical value of STENTYS self-apposing stent in treating heart attacks and will support an acceleration of its penetration in Europe.
Appointment of Michel Darnaud

Michel Darnaud joined the STENTYS Board of Directors in November 2010. A seasoned medical technology industry professional, Michel Darnaud has been President of Sorin group’s cardiopulmonary and intercontinental division since 2008.

Success of the IPO

STENTYS successful IPO resulted in a capital increase of €22.7 million. STENTYS has been listed on NYSE Euronext Paris since 25 October 2010.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, concludes: "We are very pleased with the level of activity recorded over 2010, which was in line with our business plan and reflects the adoption of our products in the countries where we started commercialization. The sales increase illustrates the growing interest in our self-apposing stent amongst cardiologists and confirms the relevance of our strategic positioning and our business plan."

• Next press release

STENTYS will publish its 2010 annual results on March 24 2011.

About Stentys

Based in Princeton, N.J., and Paris, Stentys has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., and Gonzague Issenmann, Stentys received the CE mark for its flagship products in 2010. Its self-apposing stents adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevent the malapposition problems associated with conventional stents. Stentys has commenced its marketing activities in several European countries.

More information on www.stentys.com

Contacts:

Stentys
Stanislas Piot
CFO
Tel.: +33 (0)1 44 53 99 42
stan.p@stentys.com

NewCap.
Investor relations & Financial Communications
Axelle Vuillermet / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94
stentys@newcap.fr

STENTYS is listed on NYSE Euronext Paris
ISIN: FR0010949404 – STNT